Fallopian Tube High Grade Serous Adenocarcinoma

Explore clinical trials studying Fallopian Tube High Grade Serous Adenocarcinoma. Study availability and eligibility vary by location and protocol.

9 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Fallopian Tube High Grade Serous Adenocarcinoma trial results

Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

NCT06580314

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +21 more
Locations: University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States

Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States

Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States

Alaska Oncology and Hematology LLC Anchorage, Alaska, United States

View all 676 locations

View Trial Details

Completed

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02713386

Conditions: Adnexal Diseases, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IIIA Ovarian Cancer 2014, +35 more
Locations: CTCA at Western Regional Medical Center Goodyear, Arizona, United States

Sutter Auburn Faith Hospital Auburn, California, United States

UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States

Sutter Roseville Medical Center Roseville, California, United States

View all 110 locations

View Trial Details

Active, Not Recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +33 more
Locations: Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States

Anchorage Radiation Therapy Center Anchorage, Alaska, United States

Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States

Alaska Oncology and Hematology LLC Anchorage, Alaska, United States

View all 920 locations

View Trial Details

Active, Not Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
Locations: UCHealth University of Colorado Hospital Aurora, Colorado, United States

Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States

View Trial Details

Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

NCT04616534

Conditions: Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +40 more
Locations: National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States

National Institutes of Health Clinical Center Bethesda, Maryland, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03587311

Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, +5 more
Locations: UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States

UCHealth University of Colorado Hospital Aurora, Colorado, United States

UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States

UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States

View all 23 locations

View Trial Details

Active, Not Recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927

Conditions: Adnexal Diseases, Fallopian Tube Diseases, Fallopian Tube Endometrioid Tumor, +23 more
Locations: UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States

UCHealth University of Colorado Hospital Aurora, Colorado, United States

Hartford Hospital Hartford, Connecticut, United States

Augusta University Medical Center Augusta, Georgia, United States

View all 20 locations

View Trial Details

Active, Not Recruiting

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02659241

Conditions: Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, +34 more
Locations: OHSU Knight Cancer Institute Portland, Oregon, United States

MD Anderson in The Woodlands Conroe, Texas, United States

Memorial Hermann Memorial City Medical Center Houston, Texas, United States

M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

NCT05276973

Conditions: Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +32 more
Locations: UCSF Medical Center-Mission Bay San Francisco, California, United States

Augusta University Medical Center Augusta, Georgia, United States

Cleveland Clinic Foundation Cleveland, Ohio, United States

University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States

View Trial Details

Fallopian Tube High Grade Serous Adenocarcinoma

Fallopian Tube High Grade Serous Adenocarcinoma trial results

Related conditions